An asymmetric hydrogenation route to (-)-Spongidepsin

Article abstract of DOI:10.1021/ol1018773

Figure Presented. (-)-Spongidepsin 1, a cytotoxic marine natural product, was prepared via two iridium-catalyzed hydrogenation reactions; both were highly stereoselective, giving convenient access to pivotal intermediates. This synthesis was modified to g

Full text of DOI:10.1021/ol1018773

ORGANIC
LETTERS
2010
Vol. 12, No. 19
4392-4395
An Asymmetric Hydrogenation Route To
(-)-Spongidepsin
Ye Zhu, Aurore Loudet, and Kevin Burgess*
Texas A & M UniVersity, Chemistry Department, P.O. Box 30012,
College Station, Texas 77842
burgess@tamu.edu
Received August 10, 2010
ABSTRACT
(-)-Spongidepsin 1, a cytotoxic marine natural product, was prepared via two iridium-catalyzed hydrogenation reactions; both were highly
stereoselective, giving convenient access to pivotal intermediates. This synthesis was modified to give several spongidepsin analogues, and
their cytotoxicities were compared with those of the natural product.
Typical syntheses of polyketide-derived macrolides tend to
focus on asymmetric aldol1-3 and alkylation reactions,4,5
often involving chiral auxiliaries. These processes are
frequently augmented by enzyme-mediated resolutions to
generate other chirons that are not readily available from
the chiral pool.6,7 Alternative methods, however, sometimes
increase synthetic efficiencies and expose opportunities for
analogue syntheses.
Our group has used chiral analogues of Crabtree’s catalyst
in syntheses of some pivotal chirons for preparations of
natural products, particularly in the polyketide series. This
communication describes how those methods were applied
to the preparation of (-)-spongidepsin 1 (Figure 1)8 and
Figure 1. Retrosynthesis of 1 highlighting the chirons from
stereoselective hydrogenations.
some close analogues of this structure.
(1) Brodmann, T.; Lorenz, M.; Schaeckel, R.; Simsek, S.; Kalesse, M.
Synlett 2009, 174
(2) Schetter, B.; Mahrwald, R. Angew. Chem., Int. Ed. 2006, 7506
(3) Palomo, C.; Oiarbide, M.; Garcia, J. M. Chem. Soc. ReV. 2004, 65
.
Figure 1 illustrates the target molecule containing chirons
2 and 3 that we proposed could be made via stereoselective
hydrogenations. To obtain compound 2, a Sharpless kinetic
resolution9,10 of the allylic alcohol 4 was used (Scheme 1).
.
.
(4) Horst, B.; Feringa, B. L.; Minnaard, A. J. Chem. Commun. 2010,
2535
.
(5) Hanessian, S.; Giroux, S.; Mascitti, V. Synthesis 2006, 1057
.
(6) Abate, A.; Brenna, E.; Costantini, A.; Fuganti, C.; Gatti, F. G.;
Malpezzi, L.; Serra, S. J. Org. Chem. 2006, 71, 5228
(7) Ohno, M.; Otsuka, M. In Organic Reactions; Kende, A. S., Ed.;
John Wiley & Sons, Inc.: New York, 1989; Vol. 37, p 1
.
(8) Grassia, A.; Bruno, I.; Debitus, C.; Marzocco, S.; Pinto, A.; Gomez-
Paloma, L.; Riccio, R. Tetrahedron 2001, 6257.
.
10.1021/ol1018773  2010 American Chemical Society
Published on Web 09/07/2010

altering protecting groups, or changing the alkene geometry.
In the case of 1,3-hydroxymethyl chirons we have shown
that an alkene with similar functionality, protection, and
geometry relative to 6 was hydrogenated with high stereo-
selectivity.12 The reduction of 6 to 7 occurred with similar
high selectivity. Chiron 2 was then generated from 7 via
routine oxidation, reduction, and Wittig homologation steps.
Scheme 1. Synthesis of the 1,3-Hydroxymethyl Chiron 2
Scheme 2. Synthesis of the 1,3-Dimethyl Chiron 3
Acylation, oxidative cleavage, reaction with a stabilized
Wittig reagent, and then hydride reduction gave the allylic
diol 5.
Previous studies from our group have shown that catalyst
control tends to prevail in hydrogenations of acyclic chiral
substrates11-16 using catalysts like our carbene complex
“cat.” (“cat.” is an abbreviation for “catalyst”; see graphical
abstract for structure).17,18 However, manipulation of the
alkene component in these reactions provides a mean to
optimize the “substrate-vector” such that it matches19 the
catalyst influence to maximize stereoselectivity. This can be
done by interchanging ester and alcohol functionalities,
Scheme 2 oulines how the second pivotal chiron, 3, was
obtained. Previous reports from our group have shown how
similar 1,3-dimethyl chirons can be made from the Roche
ester.14-16
To complete our synthesis of (-)-spongidepsin 1, chiron
2 was coupled with the appropriate protected N-methyl amino
acid to give the ester 12 (after removal of a BOC group).
This was then coupled with chiron 3 to form the R,ω-diene
13. Ring-closing metathesis with the “second generation”
Grubbs catalyst20,21 gave the macrocycle 14 after simulta-
neous O-deprotection and alkene hydrogenation. The final
steps in the synthesis were oxidation and generation of the
alkyne group. Proton and 13C NMR spectra of the synthetic
product 1 were compared closely with those reported in
previous syntheses (see below).22-25
(9) Gao, Y.; Klunder, J. M.; Hanson, R. M.; Masamune, H.; Ko, S. Y.;
Sharpless, K. B. J. Am. Chem. Soc. 1987, 109, 5765
(10) Pfenninger, A. Synthesis 1986, 89
(11) Zhao, J.; Burgess, K. J. Am. Chem. Soc. 2009, 131, 13236
(12) Zhu, Y.; Burgess, K. J. Am. Chem. Soc. 2008, 130, 8894
(13) Zhao, J.; Burgess, K. Org. Lett. 2009, 11, 2053
(14) Zhou, J.; Zhu, Y.; Burgess, K. Org. Lett. 2007, 9, 1391
(15) Zhou, J.; Ogle, J. W.; Fan, Y.; Banphavichit, V.; Zhu, Y.; Burgess,
K. Chem.sEur. J. 2007, 7162
(16) Zhou, J.; Burgess, K. Angew. Chem., Int. Ed. 2007, 1129
(17) Perry, M. C.; Cui, X.; Powell, M. T.; Hou, D.-R.; Reibenspies,
J. H.; Burgess, K. J. Am. Chem. Soc. 2003, 125, 113
(18) Powell, M. T.; Hou, D.-R.; Perry, M. C.; Cui, X.; Burgess, K. J. Am.
Chem. Soc. 2001, 123, 8878
.
.
.
.
.
.
.
.
Besides the amino acid-derived chirality, there are four
stereogenic centers in spongidepsin. Table 1 outlines the
origin of these chiral centers in the four previous total
syntheses of this molecule and compares them against our
.
.
(19) Masamune, S.; Choy, W.; Peterson, J. S.; Sita, L. R. Angew. Chem.,
Int. Ed. 1985, 1.
Org. Lett., Vol. 12, No. 19, 2010
4393

Table 1. Comparison of Syntheses of Spongidepsin
chiral centers
1
2
3
4
Forsyth22
Ghosh23
Cossy24
enzyme resolutiona
enzyme resolution
crotyl-stannylation (87:13)
ZACA (5.5:1.0)
hydroboration (1.0:1.0)
Evan’s alkylation (98:2.0)
asymmetric alkylation (85:15)
ZACA (3.5:1.0)
epoxide opening
bromo-lactonization (19:1.0)
SmI2-mediated (85:15)
allyl boration (not specified)
Sharpless kinetic res’n
Roche ester
ZACAb (82% ee)
Roche ester
Negishi25
this work
hydrogenation (61:1.0)
hydrogenation (34:1.0)
a Stereoselectivities are not indicated for kinetic resolution steps since they are conversion dependent. b ZACA is zirconium-mediated asymmetric
carboalumination. There are also two “formal” syntheses of spongidepsin.26,27
approach.22-25 Some key steps in the other syntheses achieve
more than creation of chiral centers (e.g., C-C bond
Scheme 3. Completion of the Synthesis of 1
formation in Negishi’s zirconium-mediated asymmetric car-
boalumination {ZACA} reactions), so they may have
advantages that are not apparent from Table 1. However,
the stereoselectivities obtained in this work compare favor-
ably with the published syntheses, and the featured hydro-
genation reactions proceed with 100% conversion to product;
therefore, these steps are highly efficient.
As far as we are aware, nothing has been reported on
structure activity relationships for spongidepsin. Conse-
quently, several intermediates in Scheme 3 were diverted to
form analogues of the target material for testing. Thus,
compounds 15 and 16 were also prepared; see Supporting
Information for the preparation of 15. Compound 16 could
be conveniently obtained via reduction of 15. Motives for
making these particular compounds were to test the effects
of increased conformational rigidity in the macrolide and
the effects of saturating the side chain on the cytotoxicity.
The cellular target for spongidepsin is unknown. Conse-
quently, we also decided to prepare two bivalent molecules
consisting of two macrolide fragments joined by a flexible
(20) Schrodi, Y.; Pederson, R. L. Aldrichimica Acta 2007, 45.
(21) Grubbs, R. H. Handbook of Metathesis; Wiley-VCH: Weinheim,
Germany; Chichester, England, 2003.
(22) Chen, J.; Forsyth, C. J. Angew. Chem., Int. Ed. 2004, 2148.
(23) Ghosh, A. K.; Xu, X. Org. Lett. 2004, 6, 2055.
(24) Ferrie, L.; Reymond, S.; Capdevielle, P.; Cossy, J. Org. Lett. 2006,
8, 3441.
(25) Zhu, G.; Negishi, E.-I. Org. Lett. 2007, 9, 2771.
(26) Chandrasekhar, S.; Yaragorla, S. R.; Sreelakshmi, L.; Reddy, C. R.
Tetrahedron 2008, 5174.
(27) Chandrasekhar, S.; Yaragorla, S. R.; Sreelakshmi, L. Tetrahedron
Lett. 2007, 7339.
linker via a “click reaction” (Scheme 4).28,29 These analogues
were designed to probe if this modification would have
significant effects on the molecular cytotoxicities; if it did,
this might implicate a homodimeric binding partner.
(28) Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angew. Chem., Int. Ed.
2001, 2004
.
(29) Meldal, M.; Tornoe, C. W. Chem. ReV. 2008, 108, 2952
.
4394
Org. Lett., Vol. 12, No. 19, 2010

Scheme 4
.
Synthesis of the Dimers of 1a
Table 2. In Vitro Antiproliferative Activity of 1 and Derivatives
15, 16, 18, and 19
compound
IC50 (µM)a
1
5.68 (0.66)b
8.27
7.32
noncytotoxic
noncytotoxic
7.45 (0.007)b
15
16
18
19
6-mercaptopurine
a Assay run for 72 h in EMEM + 2% FBS at 37 °C using human
embryonic kidney cells (HEK-293). b Literature data.8 IC50 values were
measured three times and averaged.
of 6-mercaptopurine were both significantly less (1 and 3
orders of magnitude, respectively) than reported previously.8
However, the IC50 of 6-mercaptopurine reported in ref 8 is
about 100× less than in three other literature reports (see
Supporting Information). Further, the relative cytotoxicity
of the target compound 1 and 6-mercaptopurine is almost
the same. We cannot account for these discrepancies;
nevertheless, it is possible to confidently compare the relatiVe
cytotoxicities of 6-mercaptopurine,1, and its analogues in our
assays.
Figure 2 indicates that the new monomer derivatives 15
and 16 show little effect up until 2 µM concentrations, after
which they are significantly cytotoxic, just as the natural
product is. Consequently, reduction of the alkyne side chain
or incorporation of an alkene in the macrolide has no
significant effect. Surprisingly, the bivalent molecules 18 and
19 do not show significant cytotoxicities in the same
concentration range. Compound 1 and the new derivatives
were also tested on human pancreatic carcinoma cells (Panc-
1); the IC50 values for the monomers 1, 15, and 16 were in
the same range, and the dimers were also noncytotoxic
(Supporting Information). Together, these data indicate that
incorporation of a large substituent on the alkyl chain almost
completely eliminates the cytotoxic effect, and there was no
positive effect from these bivalent analogues.
a TBTA ) tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine.
Compounds 1, 15, 16, 18, and 19 were tested in an
antiproliferative assay on human embryonic kidney (HEK-
293) cells (Figure 2), and the IC50 values measured are
Asymmetric hydrogenations via chiral analogues of Crab-
tree’s catalyst are viable for synthesis of spongidepsin.
Previous studies from this group indicate all stereoisomers
of chirons like 2 and 3 can be made via such methods. We
infer from this that syntheses of stereoisomers of this natural
product could be made via similar approaches. The results
presented here indicate that practical syntheses of other
analogue types are also possible.
Acknowledgment. Financial support for this work was
provided by The National Science Foundation (CHE-
0750193) and The Robert A. Welch Foundation (A1121).
Figure 2. Antiproliferative assay for the natural product 1 and the
new derivatives 1, 15, 16, 18, and 19 in MTT assays featuring
human embryonic kidney cells (HEK-293).
Supporting Information Available: Experimental pro-
cedures and characterization data for the new compounds
reported. This material is available free of charge via the
Internet at http://pubs.acs.org.
indicated in Table 2 relative to 6-mercaptopurine (control
cytotoxic compound). These assays were reproduced several
times; in our hands, the cytotoxicities of compound 1 and
OL1018773
Org. Lett., Vol. 12, No. 19, 2010
4395